1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Community Acquired Pneumonia - Pipeline Review, H1 2017

Community Acquired Pneumonia - Pipeline Review, H1 2017

  • February 2017
  • -
  • Global Markets Direct
  • -
  • 100 pages

Community Acquired Pneumonia - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Community Acquired Pneumonia – Pipeline Review, H1 2017, provides an overview of the Community Acquired Pneumonia (Infectious Disease) pipeline landscape.

Community-acquired pneumonia (CAP) is defined as pneumonia acquired outside a hospital or long-term care facility. Symptoms include cough, fever, shaking chills, confusion, headache and loss of appetite. Risk factors include chronic lung disease, cigarette smoking, dementia, stroke, brain injury, heart disease, liver cirrhosis and diabetes mellitus. Treatment includes antibiotics and healthy lifestyle.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Community Acquired Pneumonia – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Community Acquired Pneumonia (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Community Acquired Pneumonia (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Community Acquired Pneumonia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 5, 6, 2, 1 and 1 respectively.

Community Acquired Pneumonia (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Community Acquired Pneumonia (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Community Acquired Pneumonia (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Community Acquired Pneumonia (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Community Acquired Pneumonia (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Community Acquired Pneumonia (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Community Acquired Pneumonia (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Community Acquired Pneumonia (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table Of Contents

Community Acquired Pneumonia - Pipeline Review, H1 2017
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Community Acquired Pneumonia - Overview
Community Acquired Pneumonia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Community Acquired Pneumonia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Community Acquired Pneumonia - Companies Involved in Therapeutics Development
Aridis Pharmaceuticals LLC
BioAegis Therapeutics Inc
Biotest AG
InflaRx GmbH
ioGenetics Inc
Kyorin Pharmaceutical Co Ltd
Lascco SA
Melinta Therapeutics Inc
Merck and Co Inc
Nabriva Therapeutics AG
Paratek Pharmaceuticals Inc
TaiGen Biotechnology Co Ltd
Takeda Pharmaceutical Company Ltd
Tetraphase Pharmaceuticals Inc
TiGenix NV
Wockhardt Ltd
Community Acquired Pneumonia - Drug Profiles
BT-086 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
CAL-02 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
ceftaroline fosamil - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Cx-611 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
DBAF-301 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
delafloxacin - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
IFX-1 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
lascufloxacin - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
lefamulin acetate - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Nafithromycin - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
nemonoxacin - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
omadacycline tosylate - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
PneumoMab - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Recombinant Plasma Gelsolin Replacement for Community Acquired Pneumonia - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
solithromycin - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
tosatoxumab - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
TP-271 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Community Acquired Pneumonia - Dormant Projects
Community Acquired Pneumonia - Discontinued Products
Community Acquired Pneumonia - Product Development Milestones
Featured News and Press Releases
Feb 02, 2017: Nabriva Therapeutics Confirms No Sample Size Adjustment Required for LEAP 1 Phase 3 Trial of Lefamulin in Community Acquired Bacterial Pneumonia
Jan 18, 2017: Paratek Announces Completion of Enrollment in Omadacycline Phase 3 Community-Acquired Bacterial Pneumonia Study
Dec 29, 2016: Cempra Receives Complete Response Letter From FDA For Solithromycin NDAs
Dec 20, 2016: Nabriva Achieves 60% Randomization Target in LEAP 1 Phase 3 Trial in Community Acquired Bacterial Pneumonia
Dec 13, 2016: Paratek Advances Timing of Top-Line Data for Phase 3 Community Acquired Bacterial Pneumonia Study to the Second Quarter of 2017
Dec 05, 2016: Launch of Phase III clinical trial for the new macrolide antibiotic “T-4288” in Japan
Nov 04, 2016: FDA Advisory Committee Votes That Efficacy Results of Cempras Solithromycin Outweigh Risks for Community-Acquired Bacterial Pneumonia
Nov 01, 2016: Cempra Receives $10 Million Milestone Payment From Toyama Chemical (a Subsidiary of FUJIFILM Holdings Corporation) as Solithromycin Progresses to Phase 3 Studies in Japan
Oct 31, 2016: Nabriva Presents Research on Lefamulin at IDWeek 2016
Oct 20, 2016: Nabriva Announces Presentations at Upcoming IDWeek 2016
Aug 30, 2016: Cempra to Present Solithromycin at FDA Antimicrobial Drugs Advisory Committee Meeting on November 4, 2016
Aug 25, 2016: Cempras Pivotal Phase 3 SOLITAIRE-IV Study of IV to Oral Solithromycin Published in Clinical Infectious Diseases
Aug 23, 2016: Cempra Announces European Medicines Agency Validates MAA for Solithromycin for Treatment of CABP
Aug 11, 2016: Cempra Appoints Dr. David Zaccardelli to Board of Directors
Jul 05, 2016: Cempra Announces FDA Acceptance of Solithera New Drug Applications in the Treatment of Community-Acquired Bacterial Pneumonia
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Community Acquired Pneumonia, H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Community Acquired Pneumonia - Pipeline by Aridis Pharmaceuticals LLC, H1 2017
Community Acquired Pneumonia - Pipeline by BioAegis Therapeutics Inc, H1 2017
Community Acquired Pneumonia - Pipeline by Biotest AG, H1 2017
Community Acquired Pneumonia - Pipeline by InflaRx GmbH, H1 2017
Community Acquired Pneumonia - Pipeline by ioGenetics Inc, H1 2017
Community Acquired Pneumonia - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2017
Community Acquired Pneumonia - Pipeline by Lascco SA, H1 2017
Community Acquired Pneumonia - Pipeline by Melinta Therapeutics Inc, H1 2017
Community Acquired Pneumonia - Pipeline by Merck and Co Inc, H1 2017
Community Acquired Pneumonia - Pipeline by Nabriva Therapeutics AG, H1 2017
Community Acquired Pneumonia - Pipeline by Paratek Pharmaceuticals Inc, H1 2017
Community Acquired Pneumonia - Pipeline by TaiGen Biotechnology Co Ltd, H1 2017
Community Acquired Pneumonia - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
Community Acquired Pneumonia - Pipeline by Tetraphase Pharmaceuticals Inc, H1 2017
Community Acquired Pneumonia - Pipeline by TiGenix NV, H1 2017
Community Acquired Pneumonia - Pipeline by Wockhardt Ltd, H1 2017
Community Acquired Pneumonia - Dormant Projects, H1 2017
Community Acquired Pneumonia - Discontinued Products, H1 2017

List of Figures
Number of Products under Development for Community Acquired Pneumonia, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Targets, H1 2017
Number of Products by Stage and Targets, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
DNA Gyrase Subunit B (EC 5.99.1.3) - Pipeline Review, H2 2016

DNA Gyrase Subunit B (EC 5.99.1.3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • November 2016
  • by Global Markets Direct

DNA Gyrase Subunit B (EC 5.99.1.3) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘DNA Gyrase Subunit B (EC 5.99.1.3) - Pipeline Review, H2 2016’, provides in depth analysis on DNA Gyrase ...

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline Review, H2 2016

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • December 2016
  • by Global Markets Direct

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline Review, H2 2016 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide ...

Burkholderia Infections - Pipeline Review, H2 2016

Burkholderia Infections - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • December 2016
  • by Global Markets Direct

Burkholderia Infections - Pipeline Review, H2 2016 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Burkholderia Infections – Pipeline Review, H2 2016, provides ...

Q Fever - Pipeline Review, H2 2016

November 2016 $ 2000

ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.